Insmed Analyst Ratings
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
8 Analysts Have This To Say About Natera
Natera Analyst Ratings
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Natera Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results and Raised Its FY25 Sales Guidance Above Estimates.
Natera GAAP EPS of -$0.50 Beats by $0.12, Revenue of $501.8M Beats by $55.13M
Insmed Shares Are Trading Lower After the Company Reported Worse-than-expected Q1 Earnings and Reaffirmed Full-year Guidance Below Estimates.
Natera To Present Multiple Datasets In Breast Cancer Together With Collaborators At 2025 ESMO Breast Cancer Annual Congress In Munich
Here Are the Major Earnings After the Close Today
Here Are the Major Earnings Before the Open Tomorrow
Preview: Natera's Earnings
Natera's Prospera Heart With DQS Cuts False Positives By Over 37%, Outperforming Dd-cfDNA Percentage Alone, AJT Publication Shows
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target
Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $165
FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday
Neurocrine Biosciences Analyst Ratings
Earnings Call Summary | Neurocrine Biosciences(NBIX.US) Q1 2025 Earnings Conference
12 Health Care Stocks Moving In Monday's After-Market Session
Neurocrine Biosciences Non-GAAP EPS of $0.70 Misses by $0.39, Revenue of $572.6M Beats by $11.63M